Antibiotic Receipt During Outpatient Visits for COVID-19 in the US, From 2020 to 2022

Samuel R Wittman; Judith M Martin; Ateev Mehrotra; Kristin N Ray

doi:10.1001/jamahealthforum.2022.5429

Antibiotic Receipt During Outpatient Visits for COVID-19 in the US, From 2020 to 2022

JAMA Health Forum. 2023 Feb 3;4(2):e225429. doi: 10.1001/jamahealthforum.2022.5429.

Authors

Samuel R Wittman¹, Judith M Martin¹, Ateev Mehrotra², Kristin N Ray¹

Affiliations

¹ Department of Pediatrics, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
² Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

No abstract available

Plain language summary

This cross-sectional study examines prescribed and filled antibiotics for outpatient COVID-19 treatment among children, adolescents, and adults with commercial insurance.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / therapeutic use
COVID-19*
Drug Prescriptions
Humans
Outpatients
Respiratory Tract Infections* / drug therapy

Substances

Anti-Bacterial Agents

Grants and funding

R01 AI148159/AI/NIAID NIH HHS/United States